Clinical Trial

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 22, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-02-06; most recent amendment 2025-09-17.
Status change: Recruiting → Active, Not Recruiting 2025-09-17
Status change: Not Yet Recruiting → Recruiting 2024-03-13
Trial Details
NCT Number NCT06245915
Lead Sponsor Arsenal Biosciences, Inc.
Conditions Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Enrollment 37 participants
Start Date 2024-02-26
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-22